Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Artios Pharma Limited is currently navigating 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners within 1 distinct art unit. This concentration within a single art unit suggests a focused technical scope for the company's current filings, even as it interacts with multiple examiners. The presence of 3 pending office actions indicates an active prosecution cycle within this specific technical domain.
The busiest examiner for the portfolio is NOLAN, JASON MICHAEL, who is managing 2 of the 3 pending office actions. This means that the majority of the company's current Biotechnology & Pharmaceuticals prosecution is under the review of a single individual. With 2 distinct examiners for the 3 pending actions, the company must balance its relationship with NOLAN, JASON MICHAEL against the requirements of the other examiner assigned to the remaining action. Because all 3 pending actions are within 1 distinct art unit, the company can expect some level of technical consistency in the prior art and legal standards applied, even if the 2 distinct examiners have different personal styles.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 2 | 66.5% | -27.8% |
| KUCHARCZK, JED A | 1 | 80.2% | +16.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264079 | NOVEL PROCESS | NOLAN, JASON MICHAEL | 30d overdue |
| 18699286 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | KUCHARCZK, JED A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699286 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | KUCHARCZK, JED A | — |
| Art Unit | Apps |
|---|---|
| 1623 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701664 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18699286 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | KUCHARCZK, JED A | 1623 | §101§112DP | Non-Final OA | — | Pending | Apr 07, 2024 |
| 18264079 | NOVEL PROCESS | NOLAN, JASON MICHAEL | 1623 | §103§112Other | Non-Final OA | 30d overdue | Pending | Aug 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial